Health News

Latest articles in Health

Next-generation Alzheimer's drug shows lower brain bleed risk in trials

A next-generation Alzheimer's drug called trontinemab has shown a much lower risk of serious brain bleeds compared to existing antibody treatments, according to research presented at the Alzheimer's Association International Conference in London. The Roche-developed drug also cleared amyloid plaques from the brain more quickly, with effects lasting at least a year. Brain bleeds, known as ARIA, have been a major safety concern with current amyloid-clearing therapies like Leqembi and Kisunla.